



## Clinical Trials in Breast Cancer

Guest Editor:

**Prof. Dr. Gilles Freyer**

1. Medical Oncology Department,  
CITOHL, Hospices Civils de Lyon,  
69002 Lyon, France  
2. Faculté de Médecine et de  
Maïeutique Lyon-Sud-Charles  
Mérieux, Université Claude  
Bernard Lyon 1, 69310 Pierre-  
Bénite, France

Deadline for manuscript  
submissions:

**closed (31 May 2021)**

### Message from the Guest Editor

Dear Colleagues,

Clinical trials in oncology are still the most important method of improving our knowledge and guiding our daily clinical practice. During the last decade, the number of anticancer drugs, driven by molecularly targeted agents and immunotherapy, has grown exponentially. To date, drug innovation in oncology represents around 50% of the overall drug development in the world. Breast cancer is probably a good example of this dynamic.

The aim of this Special Issue on “Clinical Trials in Breast Cancer” is to describe the current landscape of clinical trials in surgery, radiotherapy, and medical treatments, to address methodological endpoints, and to understand how biomarkers and preclinical modelling can be better integrated.

Prof. Dr. Gilles Freyer  
*Guest Editor*





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Samuel C. Mok

Department of Gynecologic  
Oncology and Reproductive  
Medicine, The University of Texas  
MD Anderson Cancer Center,  
Houston, TX 77030, USA

## Message from the Editor-in-Chief

*Cancers* is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

## Author Benefits

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

**Journal Rank:** JCR - Q1 (Oncology) / CiteScore - Q1 (Oncology)

## Contact Us

---

Cancers Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/cancers](http://mdpi.com/journal/cancers)  
[cancers@mdpi.com](mailto:cancers@mdpi.com)  
[X@Cancers\\_MDPI](https://twitter.com/Cancers_MDPI)